Abbott Laboratories (ABT) Total Non-Current Liabilities (2009 - 2021)
Abbott Laboratories recorded quarterly Total Non-Current Liabilities of -$20.9 billion in Q4 2021, up 16.23% quarter-over-quarter from -$24.9 billion in Q4 2020, and up 16.23% year-over-year from -$18.0 billion in Q4 2020.
Abbott Laboratories' Total Non-Current Liabilities history runs 13 years deep, the most recent figure standing at -$20.9 billion for Q4 2021.
- In Q4 2021, Total Non-Current Liabilities rose 16.23% year-over-year to -$20.9 billion; the TTM figure through Dec 2021 stood at -$20.9 billion (up 16.23% YoY), while the FY2021 annual figure was -$20.9 billion, up 16.23% from the prior year.
- Total Non-Current Liabilities came in at -$20.9 billion for Q4 2021 at Abbott Laboratories, up from -$24.9 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $48.2 billion in Q4 2017 to a low of -$24.9 billion in Q4 2020.
- A 5-year average of $8.5 billion and a median of $1.3 billion in 2019 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities soared 113.68% in 2017 and plunged 2024.46% in 2020, its largest moves.
- Abbott Laboratories' Total Non-Current Liabilities stood at $48.2 billion in 2017, then decreased by 19.84% to $38.6 billion in 2018, then slumped by 96.65% to $1.3 billion in 2019, then slumped by 2024.46% to -$24.9 billion in 2020, then climbed by 16.23% to -$20.9 billion in 2021.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered -$20.9 billion, -$24.9 billion, and $1.3 billion for Q4 2021, Q4 2020, and Q4 2019 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 20.94 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 40.52 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 15.78 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 2.44 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 9.85 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 3.53 Bn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 24.21 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 3.47 Bn |
| 10 | Zimmer Biomet Holdings | 16.17 Bn | 15.75 Bn | 1.51 Bn | 9.41 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -20.89 Bn |
| Dec 31, 2020 | -24.94 Bn |
| Dec 31, 2019 | 1.30 Bn |
| Dec 31, 2018 | 38.63 Bn |
| Dec 31, 2017 | 48.19 Bn |
| Dec 31, 2016 | 22.55 Bn |
| Sep 30, 2016 | 35.33 Bn |
| Jun 30, 2016 | 36.18 Bn |
| Mar 31, 2016 | 37.15 Bn |
| Dec 31, 2015 | 36.27 Bn |
| Sep 30, 2015 | 35.82 Bn |
| Jun 30, 2015 | 40.33 Bn |
| Mar 31, 2015 | 40.85 Bn |
| Dec 31, 2014 | 35.49 Bn |
| Sep 30, 2014 | 14.64 Bn |
| Jun 30, 2014 | 13.26 Bn |
| Mar 31, 2014 | 13.67 Bn |
| Dec 31, 2013 | 38.06 Bn |
| Sep 30, 2013 | 14.83 Bn |
| Jun 30, 2013 | 14.43 Bn |
| Mar 31, 2013 | 13.97 Bn |
| Dec 31, 2012 | 67.35 Bn |
| Sep 30, 2012 | 28.34 Bn |
| Jun 30, 2012 | 29.21 Bn |
| Mar 31, 2012 | 28.65 Bn |
| Dec 31, 2011 | 55.73 Bn |
| Sep 30, 2011 | 28.51 Bn |
| Jun 30, 2011 | 28.56 Bn |
| Mar 31, 2011 | -6.78 Bn |
| Dec 31, 2010 | 3.49 Bn |
| Sep 30, 2010 | 928.66 Mn |
| Jun 30, 2010 | 1.93 Bn |
| Dec 31, 2009 | 615.56 Mn |
| Sep 30, 2009 | 24.10 Bn |
| Jun 30, 2009 | 23.45 Bn |